(TEVA/MNTA/MYL)—I take issue with the notion that thrice-weekly Copaxone truly represents an “improved dosing regimen.” Inasmuch as 7 is not divisible by 3, a thrice-weekly dosing schedule is suboptimal from a pharmacokinetic standpoint and is only marginally more convenient.
If Teva had conducted a large head-to-head trial of thrice-weekly Copaxone vs daily Copaxone, the thrice-weekly arm would probably have incurred a higher rate of AEs. However, such a trial will never be run by Teva.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”